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INTRODUCTION:
Tumor-infiltrating CD8+ T cells are strongly associated with increased survival in ovarian cancer. However, they do not work in isolation. We discovered that two other types of immune cell play an important supportive role: B cells and helper T cells (specifically, helper T cells that express a protein called FoxP3). We made this discovery by performing a systematic analysis of immune cells in ovarian cancer. We found that killer T cells are often found in small clusters together with B cells and helper T cells. Importantly, we found that patients whose tumors have these combinations of immune cells have better survival rates than patients whose tumors contain killer T cells alone. This tells us that T cells and B cells work together to attack tumors. These findings have powerful clinical implications: to enhance the immune response to ovarian cancer, we need to enhance the activity of all three types of immune cell, rather than killer T cells alone.
To explain these observations, we hypothesized that B cells serve as "organizers" that help to draw T cells into the tumor. In addition, B cells might present tumor proteins to the T cells to facilitate tumor recognition. We further hypothesized that FoxP3 helper T cells might produce cytokines that help to excite the killer T cells. To test these hypotheses, we proposed to determine which tumor proteins (antigens) are recognized by B cells and FoxP3 helper T cells in ovarian cancer. By identifying these antigens, we will be able to create new molecular tools to elucidate how the immune system recognizes and attacks ovarian cancer. The study has four tasks: Task 1. To identify tumor antigens recognized by CD20+ TIL. Significance: The immune system has a profound influence on survival from ovarian cancer. With better understanding of the immune response, it will be possible to design new treatments such as vaccines that enhance tumor immunity and increase patient survival. We envision our work will lead to a major re-think about cancer vaccines: instead of simply trying to activate killer T cells, we also need to find effective ways to activate their team mates, the B cells and FoxP3+ helper T cells.
BODY:

Task 1. To identify tumor antigens recognized by CD20+ TIL.
In this task, we proposed to identify the antigens recognized by the 3 most abundant CD20+ TIL clones from each of 3 ovarian cancer patients. To accomplish this, we proposed to clone immunoglobulin G (IgG) molecules from individual CD20+ TIL. These will be used to identify the corresponding antigens using three different approaches: candidate antigen assays, cDNA library screening, and mass spectrometry. 
Generating IgG and TCR profiles from ovarian tumor specimens
To identify the 3 most abundant IgG (for Task 1) and TCR clones (for Task 2) in each patient's tumor, we are using deep sequencing methods developed in the Holt lab. Our approach for deep sequence analysis of T cell receptor (TCR) beta chain diversity has been previously described (1, 2) , and we have recently made adaptations to enable B cell receptor (BCR) heavy chain profiling and sample multiplexing, as described below. For the present investigation, we isolated total RNA from bulk ascites from the three HGSC ovarian cancer study subjects at three different timepoints (the time of primary disease, at first recurrence, and at second recurrence). First strand cDNA was synthesized from total RNA using either TCR beta chain or BCR heavy chain gene-specific primers, and this cDNA was then used as template to amplify the CDR3 sequences from each receptor population by PCR. The CDR3 region is the site of VDJ recombination and is the most highly variable and thus most informative region for the purpose of profiling repertoire diversity. The PCR primers were tagged with unique, 6 base pair, error tolerant barcode sequences. A different barcode was used for each individual sample. The CDR3 amplicons were then subjected to several additional rounds of nested PCR using primers tailed with Illumina adapter sequences necessary for annealing to the Illumina flow cell surface for massively parallel sequencing. The samples were pooled and sequenced using a single flow cell and the Illumina miSeq platform. Sequence data was then de-convoluted based on the barcode identifiers, and the TCR and BCR CDR3 sequences were filtered to remove low quality reads, then clustered using standard bioinformatic methods. Clustering was done to determine the number of distinct CDR3 sequences present in each sample, which reflects the diversity of distinct T-cell and B-cell clonotypes with the original ascites specimens. Prior to reverse transcription and PCR each sample was spiked with RNA from a single, known clonotype in order to monitor PCR and sequence error rates and the efficiency of sequence recovery.
So far, we have filtered and analyzed the sequence data derived from specimens taken from each of the three timepoints for one of the three study subjects. We obtained over 30,000 total TCR beta chain CDR3 sequences from each of these three samples, and over 15,000 total BCR heavy chain CDR3 sequences from each of these same three samples. These collapsed, upon clustering, into a much smaller number of distinct sequences. Specifically there were 1,598 distinct TCR sequences and 688 distinct BCR sequences observed per sample. However, as expected, the majority of these unique sequences were "singletons", representing rare clonotypes, with the bulk of the accumulated sequence data from each sample represented approximately 30 clonotypes per sample. Thus the ascites repertories are polyclonal, but not to the same extent as peripheral blood, where previously we have been able to detect over a million distinct sequences from a single sample by deep sequencing. Interestingly, 18 of the BCR clonotypes were detectable at all three timepoints, albeit with varying abundance, but the TCR clonotypes were much more sample specific, with only one TCR clonotype being present in all three samples.
Amplification of matched IgG heavy and light chains by single-cell RT-PCR
Single cell sorting and PCR amplification of matched immunoglobulin (Ig) heavy and light chains from tumor-infiltrating B lymphocytes is being accomplished via the methods of Tiller et al. (3) . Single B cells are isolated based on their surface expression of CD19, CD20 and IgG using a BD Influx cell sorter. Individual cells are sorted directly into single wells of 96-well PCR plates. Reverse transcription is accomplished directly within the sorting plate, which yields cDNA corresponding to the original single cell. This cDNA is then split equally between four separate PCR reactions, one each for the variable portions of Ig heavy, kappa, and lambda, and 6 one for the control housekeeping gene GAPDH. The variable portions of the immunoglobulin genes are then amplified by sequential nested multiplex PCR using primer sets known to amplify all human variable and joining gene segments and containing restriction enzyme cut sites to facilitate downstream molecular cloning. To date we have successfully amplified matched pairs of Ig genes from B cells isolated from the tumors of three high-grade serous ovarian cancer patients (Figure 1 ). Roughly 70% of all sorting wells yield amplification of at least one B cell-specific gene product, while about 10-25% yield matched pairs of heavy and light chains. In total, we have successfully amplified 28 pairs of Ig genes from the 3 patients.
Cloning of CDR3 regions into IgG expression vectors
Molecular cloning of the PCR amplified variable portions of matched heavy and light chain genes derived from single sorted tumor infiltrating B cells is accomplished by standard techniques. All pairs that have been amplified have subsequently been cloned into appropriate expression vectors containing the signal sequence and constant portions of the corresponding germline immunoglobulin chain (heavy, kappa, lambda). Once inserted into these expression vectors, the DNA sequence of each immunoglobulin chain is determined by Sanger sequencing. Sequences for each of the pairs of heavy and light chains have been obtained ( Figure 2 ). We are currently evaluating the prevalence of each immunoglobulin heavy sequence by sequencing samples prepared by conventional RT-PCR of bulk tumor preparations.
Preparation of recombinant IgG (rIgG)
To produce recombinant IgG, two expression vectors encoding cloned matched heavy and light chain variable portions are co-transfected into log-phase 293T cells. This transient transfection is accomplished by a calcium phosphate precipitation method. After seven days in culture, the supernatant is harvested and assessed for the presence of rIgG by human IgGspecific western blot. Fully assembled IgG molecules (~150 kDa) are observed in the supernatant of 80-90% of culture transfected with different pairs of expression vectors ( Figure 3 ) under non-reducing conditions. To isolate rIgG from the culture supernatant, it is concentrated and run over protein G sepharose columns. Captured IgG molecules are eluted at low pH and the resulting eluate is neutralized and desalted. Further concentration and assessment of purity is accomplished by BCA assay and additional western blot analysis. To date, 11 recombinant antibodies have successfully been expressed in vitro from 14 different matched Ig pairs. Based on this, we expect to have an 80% success rate in the production of rIgG from the remaining cloned Ig pairs. Term: 2 years PI: Jeremy Wulff, Co-applicant: Brad Nelson The major goal of this project is to develop small molecules that enhance anti-tumor T cell responses by inhibiting the PD1-PDL1 interaction.
CONCLUSION:
Overall, this study is progressing on schedule and on budget, with no major deviations from the original proposal. We have developed the necessary methods to complete Tasks 1 and 2, which will enable progress to Tasks 3 and 4 as originally scheduled. We published 10 relevant manuscripts in 2012-2013, and 16 with indirect relevance. Additional funding has been received from several other agencies, enhancing the strength of our cancer immunology research program.
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1. For cDNA synthesis we use a mix of TCRa and TCRb gene-specific 3' primers, and the common SMRT template switching method (Clontech) to add 5' cDNA priming sites. In step 1, the gene-specific oligos (a-1 and b-1) prime reverse transcription, which adds the 5' anchor sequence provided by the template switching oligos TS-1 and TS-2. The tail sequence of TS-1 (pink) is the reverse complement of the TS-2 tail sequence (blue). These complementary tail sequences are thereby incorporated into the reverse transcription products. In step 2, the complementary sequences incorporated into the first strand cDNA prime bidirectonal extension to yield a single double stranded DNA fragment comprised of the two TCR subunits in tandem that serve as template for further PCR amplification. By chance, fusions may be both TCRα or both TCRβ, but these do not amplify due to suppressive self annealing, and paried αβ chains are the main PCR product. B. Using total RNA from Jurkat cells (a human CD4+ T cell line that expresses a distinct αβTCR) we can effectively amplify the approximately 1.3 Kb abTCR fusion product. C. Verification of the Jurkat αβTCR fusion product by capillary sequencing.
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Introduction
Each year, over 220 000 women are diagnosed with ovarian cancer and 140 000 die of the disease [1] . Of the four major histological subtypes of epithelial ovarian cancer, high-grade serous carcinoma (HGSC) is the most common and fatal [2, 3] . HGSC tumours are thought to arise from the ovarian surface epithelium and the fimbrial region of the Fallopian tubes [4] . Our knowledge of the mutational landscape of HGSC is improving. Approximately 13-15% of HGSC cases are associated with germline mutations in BRCA1 and BRCA2 [5, 6] , and additional susceptibility genes are known to alter the BRCA1/2 DNA repair pathway (eg RAD51C, RAD51D, BRIP1, BARD1, CHEK2, MRE11A, NBN, PALB2, and RAD50 [7] ). Moreover, at least one-third of sporadic HGSC cases show inactivation of the BRCA1 or BRCA2 pathways through acquired mutations or gene silencing by DNA methylation [8] such that altogether, homologous recombination-based DNA repair is defective in about half of HGSC cases [9] . In addition, the tumour suppressor gene TP53 is mutated in over 96% of HGSCs [9, 10] . Other commonly mutated genes in HGSC include FAT3, CSMD3, NF1, RB1, GABRA6, and CDK12 [9] . Finally, a common gene fusion involving ESRRA and C11orf20 is found in 10-15% of HGSCs [11] .
Treatment of HGSC typically comprises platinumbased chemotherapeutic agents including cisplatin, carboplatin, and oxaliplatin. These compounds exert 516 M Castellarin et al an anti-tumour effect by inducing intra-strand and inter-strand crosslinks in genomic DNA and are cell cycle-non-specific in action. Ovarian cancer cells with inactivating mutations in the BRCA1 or BRCA2 genes are more prone to the DNA-damaging effects of platinum compounds. However, platinum chemoresistance can arise through a variety of mechanisms in HGSC, including acquired mutations that restore the BRCA1 and BRCA2 open reading frames [12] [13] [14] [15] [16] . Additionally, drug resistance in relapsed tumours can result from genetic alterations that affect drug efflux, drug metabolism, intracellular signalling, membrane receptors, apoptotic signalling, and interference with cell replication [17] .
There is increasing appreciation for the genetic heterogeneity of epithelial cancers within individual patients [18] [19] [20] [21] [22] [23] . The presence of multiple tumour clones in a patient creates the opportunity for evolutionary selection during treatment. Indeed, a previous study of recurrent HGSC using FISH, SNP arrays, and array CGH concluded that chemotherapy-resistant clones arise from minor clones present in primary tumours [24] . However, the extent to which recurrent tumours further evolve by accumulating additional mutations has yet to be systematically addressed in HGSC. Here, we performed whole exome sequencing of genomic DNA from tumour cells obtained from ascites of three HGSC patients at multiple time points (primary treatment, first recurrence, and second recurrence). We inferred tumour clonality and relapse-associated mutations by analysing trends in mutant allele frequencies. The possible functional consequences of mutations were assessed by pathway analysis. Furthermore, to gain a more comprehensive view of HGSC genetic susceptibility for these patients, we investigated the coincidence of germline and somatic variants within gene interaction networks.
Materials and methods
Clinical specimens
Biospecimens and clinical data were collected with informed patient consent through a prospective study entitled BC Cancer Agency's Tumor Tissue Repository/Immune Response to Ovarian Cancer (IROC), which was approved by the Research Ethics Board of the BC Cancer Agency and the University of British Columbia. Inclusion criteria included a diagnosis of HGSC, standard treatment with surgery followed by platinum-based chemotherapy (with or without taxanes), and biospecimen availability. Peripheral blood mononuclear cells (PBMCs) and primary ascites specimens were collected at the time of surgery. Recurrent ascites specimens were collected during palliative paracentesis. Ascites cells were pelleted by centrifugation, cryopreserved immediately, and stored in liquid nitrogen.
Tumour cell enrichment
Bulk ascites cells were thawed and resuspended in complete RPMI medium (cRPMI; RPMI 1640, 10% FBS, HEPES, L-glutamine, β-mercaptoethanol) at a concentration of 10 7 cells per 80 µl. To remove haematopoietic cells, 20 µl of anti-human CD45 microbeads (Miltenyi, Bergisch Gladbach, Germany) was added per 10 7 total cells and the mixture was incubated at 4
• C for 15 min. Cells were washed twice with 10 ml of cRPMI and then passed over an LS column (Miltenyi) that had been pre-wetted with 0.5 ml of cRPMI. CD45− cells passing through the column were collected, pelleted, and snap frozen at −80
• C for subsequent DNA preparation.
Exome library construction and sequencing
Genomic DNA (gDNA) was isolated, acoustically sheared, size-selected by polyacrylamide gel electrophoresis (PAGE), and end-polished. gDNA fragments were ligated with Illumina library adapters and amplified with Illumina sequencing primers (Illumina, San Diego, CA, USA). The library was then enriched for exon sequences using the Agilent Sureselect Human All Exon 50 Mb kit [25] according to the manufacturer's instructions (Agilent Technologies, Santa Clara, CA, USA). The exome fraction was subjected to massively parallel sequencing on the Illumina platform. Between 50 and 90 million paired 100 bp raw reads were obtained from each sample.
Bioinformatic analysis
The short Illumina sequence reads were aligned to the human genome (hg18) using the Burrows-Wheeler Aligner (BWA) [26] . Single nucleotide variant (SNV) detection was performed using Samtools varfilter [27] and SNVMix1 [28] software to identify high-quality, novel, protein-coding variants between the sample sequence and the human reference sequences. Insertions and deletions were detected using Samtools varfilter and then selected as protein-coding variants as delineated in the Hg18 reference sequence. Somatic mutations were determined by subtracting variants found in matched normal samples. The false-negative rate for SNVs was reduced by selecting those that were found by both Samtools and SNVMix1 and by reducing mapping errors using a targeted de novo assembler, TASR [29] . All somatic variants were manually curated using the Integrative Genome Viewer (IGV) [30] . Germline SNVs were identified from the exome data and were considered homozygous if they had a greater than 80% probability of being homozygous as determined by SNVMix1. Genomic coordinates for the germline and somatic variants were converted from the hg18 reference genome to the hg19 reference genome using the UCSC Lift Genome Annotations tool [31] . Biological pathway analysis was performed using both the GeneMania plugin [32] in Cytoscape v2.8.3 [33] and Ingenuity Pathways Analysis [35] annotated functions of gene clusters were predicted based on physical interactions and pathway data sources using GeneMania [36] . GeneMania estimates the false discovery rate (FDR), the proportion of positives that are expected to be false positives, as q-values by using the Benjamini-Hochberg procedure, and it is this number that we report. Nodes were partitioned according to network modules using the Reactome FI Cytoscape plugin [37] and network diagrams were depicted using the circular layout in Cytoscape.
Sequence validation
Sequence validation was performed by PCR amplification of targeted mutant loci followed by Illumina sequencing of indexed products on a single cell lane of 100 bp paired-end reads on an Illumina HiSeq platform. The short Illumina sequence reads were then aligned to the human genome (hg18) using the BWA [26] . Variant detection was performed using Samtools mpileup [27] and validated somatic variants were visually curated using IGV [30] .
Results
Patient selection and clinical course
We selected three HGSC patients for whom matched ascites tumour specimens were available from the time of primary surgery and two subsequent recurrences. As fluid, ascites had the advantage of providing serial samples unrestricted to any specific tumour region. As shown in Figure 1 , patient 1 received adjuvant chemotherapy with five cycles of carboplatin and paclitaxel. In response to recurrence of disease 8 months after completion of the first round of therapy, she received six cycles of carboplatin with gemcitabine, which slowed tumour progression for several months. Upon further progression, she received two courses of etoposide, to which she failed to respond. Patient 2 received adjuvant chemotherapy with six cycles of carboplatin. In response to progressive disease, she was treated with seven cycles of paclitaxel, which stabilized her disease for about 2 months. Upon further progression, she received one cycle of gemcitabine, to which she failed to respond. Finally, patient 3 received adjuvant chemotherapy with six cycles of carboplatin and paclitaxel, which led to complete remission. Upon disease recurrence at 9 months, she received six cycles of carboplatin with gemcitabine, which led to a second complete remission. Upon disease recurrence, she received three cycles of pegylated liposomal doxorubicin, to which she failed to respond.
Identification of somatic mutations by whole exome sequencing
Whole exome sequencing was performed to profile somatic mutations in ascites tumour samples. Single nucleotide variants and insertions/deletions (indels) were validated by targeted re-sequencing at a depth of ≥ 50 000 reads using germline DNA for comparison. We identified a total of 22-40 somatic variants (somatic point mutations plus somatic indels) per (Tables 1 and 2) . Table 1 lists all somatic point mutations, their allelic frequencies, and their predicted effects on protein function according to the SIFT program [38] . Of the 88 somatic point mutations that we found, only two have been previously reported, one in BRCA1 and the other in CSMD3 [39] . Of the remaining 86 somatic point mutations, 69 were within genes previously found to be mutated in ovarian serous carcinoma according to the Catalogue of Somatic Mutations in Cancer (COSMIC) database [40] . By SIFT analysis, 28% of somatic point mutations were predicted at high confidence to impair protein function. In addition to somatic point mutations, we found five somatic indels, which involved the genes TP53 (patient 1), MACF1 (patient 2), and CAPN7, DMD, and OR5A1 (patient 3) ( Table 2 ). The only gene found to contain a somatic point mutation or indel in all three patients was TP53.
Clonal structure and evolution of tumours Somatic variants were subjected to high-depth targeted re-sequencing using tumour samples from all three time points. This allowed quantification of allele frequencies over time, even for mutations that fell below the limit of detection in the original exome sequencing libraries. We found that the vast majority of mutations that were present in relapse samples were present in primary samples (Table 1) . Likewise, the majority of mutations that were present in primary samples persisted in relapse samples (Table 1) .
We used a hierarchical clustering model to infer tumour clonality based on concordant changes in mutant allele frequencies (Figure 2 ). Mutations from patient 1 formed three distinct clusters, which may reflect three distinct clonal populations. Cluster 1 was markedly more abundant than the other two clusters and contained a heterozygous TP53 mutation. The relapse tumours from patient 1 showed a doubling in allelic frequency of the TP53 mutation, suggesting a loss of heterozygosity at the TP53 locus ( Table 1) . The relative proportions of the three clusters did not change significantly across the three time points. One exception was the PLXB2 mutation in cluster 1, which occurred at a frequency of 25% in the primary tumour sample but close to 100% in relapse samples. This suggests that the PLXB2 mutation occurred after the other cluster 1 mutations and that a subclone expressing this mutation increased in frequency at relapse compared with primary tissue. Patient 2 showed four major clusters of mutations. As with patient 1, the cluster containing mutant TP53 was dominant at all time points. Patient 3 showed five clusters of mutations and much more complex dynamics, possibly reflecting the dramatic changes in tumour burden seen with this patient during chemotherapy (Figure 1) . Again, the cluster containing mutant TP53 (cluster 1) was dominant at all time points. Cluster 3 increased in prevalence at first relapse and remained prominent at second relapse. Cluster 5 showed the opposite pattern, being prevalent in the primary tumour but absent at relapse.
Functional annotation of mutant genes
Mutant genes from each cluster were functionally annotated using the Gene Ontology (GO) [35] . Despite the lack of shared mutations among patients, the mutations fell into several shared functional categories. The predominant cluster from all three patients had cell cycle checkpoint function. In addition, statistically significant functional annotations that involved Golgi vesicles were found in cluster 3 from patient 1 (FDR = 9.3 × 10 −14 ), cluster 4 from patient 2 (FDR = 1.47 × 10 −2 ), and cluster 2 from patient 3 (FDR = 1.38 × 10 −8 ).
Analysis of shared pathways among somatic mutations and germline variants
Germline mutations can increase the risk of developing cancer but further somatic mutations are needed to cause the actual onset of the disease. In HGSC, the BRCA1, BRCA2, and TP53 genes frequently harbour somatic mutations, and germline mutations can contribute to a familial predisposition. In general, tumourigenesis and disease progression require multiple, parallel pathways that can be altered by either germline or somatic genetic lesions [41] . SNPs that are shared among these patients may constitute a common predisposition to perturbed pathways that can become altered further by somatic mutations. We asked whether in these patients, somatically mutated genes were related to genes carrying germline coding variation. We identified 972 high-confidence homozygous, non-synonymous SNPs that were common to all three patients. These SNPs were contained within 804 distinct genes (Supplementary Table 1 ). Of the germline SNPs that resulted in SIFT scores, 3% were predicted at high confidence to impair protein function. Using the Cytoscape GeneMania plugin [32] and the Reactome FI plugin [37] , we performed network analysis on both the shared homozygous germline variants and the somatic variants ( Figure 3 ). The network revealed connectivity among somatic and germline variants that defined highly connected modules. The top two interacting nodes that were represented as network hubs were TP53 and fibronectin 1. The sets of mutated genes within each module were then assessed for functional annotation based on GO terms. The module with the largest number of nodes (57) 
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with the total number of somatic versus germline variants, 93/804 (11.6%). The modules for 'extracellular matrix' and 'G2/M transition of mitotic cell cycle' also contained both somatic mutations and germline variants. These results suggest possible interplay between SNPs that may impart a hereditary predisposition to HGSC and subsequently acquired somatic mutations.
Discussion
Epithelial ovarian cancer is highly responsive to frontline treatment, but relapse with chemotherapy-resistant disease occurs in the majority of cases. To assess disease progression, we used CD45− sorted ascites cells as a surrogate for solid tumour biopsies since recurrent samples are not surgically resected and ascites is the only available source of tumour in most cases. We sequenced the exomes of primary, first, and second relapse tumours and discovered mutations affecting multiple cellular processes and structures, including cell cycle control, Golgi vesicles, DNA repair, and extracellular matrix. Remarkably, 89% of mutations found in relapse tumours were present in matched primary tumours, indicating that recurrent HGSC arises from the selective persistence or outgrowth of pre-existing tumour clones, with relatively little accumulation of new mutations. Our results raise the encouraging possibility that improved targeting of mutated pathways in primary tumours could potentially prevent the development of recurrent disease.
Our finding that the majority of mutations in recurrent disease were present in the primary tumour sample is consistent with a prior study of HGSC that used FISH, SNP arrays, and array CGH [24] . Given the genotoxic effects of platinum-based chemotherapy, it is surprising that so few new mutations were found in relapse tumours. Rather, our data indicate that chemotherapy failed to destroy the major clones present in the primary tumour, as indicated by the fact that fewer than 10% of mutations were lost after treatment. An exception was patient 3, who responded dramatically to her first round of treatment based on decreased CA-125 levels ( Figure 1 ) and complete disappearance of a mutational cluster (cluster 5 in Figure 2 ). Patient 3 also showed the greatest number of new mutations in relapse samples. Relapsespecific mutations observed in patients 1 and 2 included PREX2 , which has recently been reported in metastatic melanomas [42] , and AP1b1 , which is associated with vesicle formation in the trans-Golgi network [43] . It is unknown whether these mutations were due to the DNA-damaging effects of chemotherapy or the expansion of a minor tumour clone from the primary tumour.
In all three patients, GO annotated somatic mutation clusters were seen that involved either the Golgi vesicle or Golgi transport (Figure 2) . Similarly, network analysis of somatic mutations and germline SNPs revealed two modules that were annotated for the transGolgi network and Golgi vesicle targeting (Figure 3) . The Golgi apparatus has been previously implicated in cancer processes such as drug efflux, apoptosis, and proliferation. Cisplatin is sequestered by the Golgi in ovarian carcinoma cells, which may be necessary for platinum efflux [44] . The Golgi has also been implicated in apoptosis by such means as compartmentalizing caspase 2, triggering mitochondrial membrane permeability, releasing death receptors to the cell surface, and sensing misfolded proteins [45] . Additionally, anti-cancer drugs such as 2-phenyl benzimidazole (2-PB) disrupt the Golgi apparatus, which leads to reduced cell proliferation and tumour growth [46] .
Germline SNPs and somatic mutations were also found in the extracellular matrix (ECM) pathway, including collagens, laminins, integrins, syndecan 1, and fibronectin 1. These proteins are involved in cell adhesion, cell signalling, and cytoskeletal organization, and alterations to ECM pathways have been found during the evolution of other cancers [20, 47] but not previously in HGSC.
Germline and somatic variants were found in pathways such as p53, cell cycle progression, and DNA repair (Figure 3 ), which are known HGSC susceptibility pathways [7] . TP53 was the only gene found to harbour a somatic mutation in all three patients, while BRCA1 was somatically mutated in patient 1 and all three patients shared the same germline SNPs in BRCA2 and ATM (Table 1, Supplementary Table 1 and  Supplementary Table 2 ). An apparent chemotherapysusceptible clone, cluster 5 from patient 3, contained a highly abundant RGS6 mutation, which is a gene that has been shown to be associated with cancer risk [48] . More recently, RGS6 has been reported to activate the intrinsic pathway of apoptosis in a p53-independent manner and affected doxorubicin susceptibility in breast cancer cells [49] .
Cancer pathogenesis can occur through the loss of both alleles in a tumour suppressor gene in the classical 'two-hit' hypothesis of tumour suppression or through a more subtle, titrated loss of tumour suppressor gene function as described by a continuum model of tumour suppression [50] . Consistent with the continuum model, tumourigenesis can be initiated by p53 haploinsufficiency, as seen in patients with Li-Fraumeni syndrome and, it appears, patient 1 ( Table 1 ). The continuum model of disease progression may extend beyond tumour suppressor genes, since we observed several examples of pathways that were altered by germline variants and became further perturbed by somatic mutations (Figure 3) .
We have shown here that HGSC tumours are heterogeneous, with multiple, genetically distinct clones present prior to treatment. Most of the mutations in primary tumours persist despite treatment, suggesting that most clones are able to evade current chemotherapy treatments. Furthermore, there is little accumulation of new mutations in recurrent tumours, even after two rounds of chemotherapy. Encouragingly, we found novel mutations in the Golgi and ECM pathways, which may offer new therapeutic targets for HGSC. Moreover, the relatively stable nature of the HGSC genome over time provides hope that improved therapeutic targeting of the genetic lesions present in primary tumours will ultimately be effective for preventing tumour recurrence. 
Introduction
High-grade serous ovarian cancer (hereafter abbreviated HGSC) is the most common and lethal subtype of ovarian cancer, with a 5-year survival rate of only 30% (1). Although most patients are highly responsive to primary surgery and chemotherapy, the majority experience recurrence within 1 to 3 years and ultimately succumb to their disease (2). Despite these unfortunate statistics, a subset of patients experience prolonged disease-free survival. in tumor immunity can be gained from studies of B cell infiltrates in autoimmunity and solid organ transplantation (21) (22) (23) (24) (25) (26) (27) (28) (29) . In renal allografts, the presence of graft-infiltrating B cells is a sign of impending rejection (25) . Intriguingly, in this setting, infiltrating B cells are uncoupled from donorspecific serologic responses (29) and instead are thought to facilitate T-cell responses by serving as APC and by releasing cytokines and chemokines that recruit T cells to affected tissues. Indeed, treatment of renal allograft recipients with anti-CD20 antibody (rituximab) not only depletes B cells but also results in reduced expression of T-cell-associated genes (24) . Similar mechanisms are thought to operate in autoimmunity. In a murine xenograft model of rheumatoid arthritis, depletion of B cells with anti-CD20 antibody lead to the disappearance of not only infiltrating B cells but also reduced activation and infiltration of T cells (27 
Materials and Methods
Study subjects and sample processing Studies were carried out with 3 HGSC patient cohorts. Cohort A (n ¼ 40), assembled through a prospective study entitled Immune Response to Ovarian Cancer (IROC), included serial serum samples, cryopreserved cells, frozen tissue, and formalin-fixed paraffin-embedded (FFPE) tissue blocks. Clinical characteristics are described in Supplementary Table S1 . Cohort B was a small retrospective cohort (n ¼ 30) with matched serum samples and FFPE tissue blocks. The clinical characteristics were similar to those of cohort A. Cohort C (n ¼ 194) was from a large previously published retrospective cohort, which included only FFPE tissue blocks (6, 30) . The clinical characteristics were similar to those of cohort A, with the exception that all patients were optimally debulked during primary surgery. For ELISA experiments, the control group consisted of age-matched women with both ovaries intact and no personal history of cancer. All specimens and clinical data were collected with informed patient consent through the BC Cancer Agency's Tumour Tissue Repository (cohort A) or OvCaRe (cohorts B and C) under protocols approved by the Research Ethics Board of the BC Cancer Agency and the University of British Columbia.
Tumor tissue was obtained at the time of primary cytoreductive surgery before any other treatment. Samples were either preserved in formalin and processed in paraffin for preparation of tissue microarrays, frozen in OCT medium for sectioning and DNA extraction, or processed into singlecell suspensions as previously described (31) . Serum was processed using serum separator tubes, aliquoted, and stored at À80 C. Pretreatment serum was collected before primary surgery (except for patient IROC037, which was collected 1 month postsurgery), and subsequent samples were collected approximately 3, 6, 12, and 24 months following surgery. Peripheral blood mononuclear cells (PBMC) from patients and healthy controls were collected in heparinized Vacutainer tubes, isolated by Ficoll density centrifugation and cryopreserved.
Immunohistochemistry
For cohort A, a tissue microarray (TMA) was constructed using a manual tissue arrayer from Beecher Instruments. The TMA consisted of duplicate 1-mm cores taken from representative central regions of nonnecrotic tumor epithelium with some stromal regions, as defined upon review of hematoxylin and eosin-stained sections by a pathologist (PHW). For cohorts B and C, TMAs were constructed in a similar manner but consisted of 0.6-mm duplicate cores and were constructed using a Pathology Devices tissue arrayer. TMAs from cohorts A and B were prepared and
Translational Relevance
High-grade serous ovarian cancer has a 5-year survival rate of only 30%, so there is an urgent need for improved treatments. Recent studies have provided unequivocal evidence that patients who mount strong immune responses against their tumor experience markedly prolonged survival. Although tumor-infiltrating T cells are clearly important for tumor immunity, we have recently shown an equally prominent role for B cells. Here, we investigate the underlying mechanisms. Unexpectedly, we found that tumor-infiltrating B cells were uncoupled from antibody responses to common tumor antigens. Instead, they colocalized with T cells and showed characteristics of antigen-presenting cells. The presence of both B cells and T cells in tumors was associated with better prognosis than T cells alone. Thus, tumor-infiltrating B cells seem to support T-cell responses to cancer. Immunotherapeutic strategies that engage both lymphocyte subsets may have more potent and sustained antitumor effects. stained as previously described (31) using an anti-CD20 rabbit polyclonal primary antibody (catalog #RB-9013; Lab Vision). The cohort C TMA was prepared and stained as previously described (30) .
Scoring of TMAs for cohorts A and B was carried out in a blinded fashion by a pathologist (PHW). Tumor cores were initially scored by assessing at low magnification the proportion of each core that comprised tumor or stroma and then scoring at 20Â magnification the number of positively stained TIL within the core area (through direct counting up to 20 or by estimation in 10s when in excess of this number), as well as the proportion of TIL present in tumor epithelium versus stroma. For cohort C, cores were scored either 0 (no cells present), 1 (1-5 cells), 2 (6-19 cells), or 3 (20þ cells) and then binarized to negative versus positive (score 0 vs. scores 1, 2, and 3). This binarization was used to generate the survival data in Fig. 6E . Survival curves were not determined for cohorts A and B due to small sample size and insufficient follow-up time.
Two-color IHC was carried out on FFPE sections following deparaffinization in a decloaking chamber (Biocare Medical) with Diva Decloaker. Samples were blocked with Peroxidased-1 and Background Sniper and then labeled with a cocktail of antibodies to CD8 (mouse monoclonal C8/144B; Cell Marque) and CD20 (rabbit polyclonal catalog # E2560; Spring Bio) for 30 minutes at room temperature. The two-color polymer kit Mach-2 DS2 was used to amplify the primary signal, and Betazoid DAB and Warp Red chromogens were used for detection. Slides were counterstained with hematoxylin. All staining reagents were from Biocare Medical. Images were captured using an Olympus BX53 microscope and Nuance multispectral imaging system (CRI).
Flow cytometry
Cryopreserved cells were labeled with antibodies listed in Supplementary Table S2 . Data were acquired using a BD Influx cell sorter (BD Biosciences) and analyzed using FlowJo software (Tree Star). All samples are gated on lymphocytes based on forward and side scatter plots. Antibody specificity was tested using matched isotypes and fluorescence-minus-one controls.
Idiotype sequencing
Six independent PCRs were carried out using primer pairs designed to amplify VH1, VH2, VH3, VH4, VH5, and VH6 sequences. After amplification, PCRs were combined in pools of two and cloned into the pENTR/D-TOPO plasmid vector (Invitrogen). At the BC Cancer Agency's Genome Sciences Centre (Vancouver, Canada), plasmids were electroporated into DH10B T1 phage-resistant cells, plated onto selective growth media, and robotically arrayed in 384-well plates. Plasmid DNAs were then extracted and BigDye Terminator (ABI) cycle sequenced on ABI 3730 sequencers using conventional procedures.
DNA sequences were analyzed using the IMGT/V-QUEST tool (32) of IMGT, the international ImMunoGeneTics information system (33) . Up to 96 sequences were analyzed from each tumor sample. Sequences were compared with germline sequences to identify somatic hypermutations, and V-D-J junctions were compared to identify clonal sequences.
ELISA to detect serum antibodies to NY-ESO-1 and p53
cDNAs encoding the autoantigens NY-ESO-1 and p53 were amplified by reverse transcriptase PCR (RT-PCR) from the ovarian cancer cell line OVCAR3, cloned into the pDEST17 vector, and used for recombinant protein production, as previously described (NY-ESO-1; ref. 31) or using the primer pair: 5 0 -CACCATGGAGGAGCCGCAGTCA and 5 0 -TTAGTCTGAGTCAGGCCCTTCTGT (p53). Serum was assayed in triplicate for IgG antibodies to recombinant NY-ESO-1 and p53 by ELISA as previously described (31) . Triplicate measurements of control sera were used to establish the mean and SD of autoantibody responses to each antigen. For cancer patients, autoantibody responses were scored as positive if they were significantly greater than the mean of the controls. Specifically, the mean of the controls was subtracted from individual patient responses, which were then divided by the SD of all controls. Responses greater than 3.0 SDs from the control mean were considered positive (34) . Association between CD20 status and autoantibody responses was assessed using the Fisher exact test with a 2-tailed P value (GraphPad Prism). To assess quantitative changes over time, autoantibody titers were determined using a method similar to Gnjatic and colleagues (19) . Each serum sample was subjected to 4-fold serial dilutions from 1:100 to 1:6,553,600. Reciprocal titers were determined based on the highest dilution that gave a positive response against NY-ESO-1. The cutoff for positive responses was based on optical density values greater than twice the value of the average optical density of the 4 lowest dilutions of a pool of 5 healthy donor serum samples.
Results
CD20
þ TIL are mature, antigen-experienced B cells
We previously reported that CD20 þ TIL are strongly associated with prolonged survival in HGSC (6). To investigate potential immunologic mechanisms underlying this association, we first assessed whether CD20 þ TIL exhibit characteristics of antigen-experienced B cells. We selected 9 HGSC tumors containing CD20 þ TIL, as determined by IHC (Fig. 1A) and used multiparameter flow cytometry to assess surface immunoglobulin expression on CD20 þ B cells from tumor tissue and matched blood samples. In peripheral blood, HGSC patients showed a normal distribution of
þ B cells, which was similar to cancer-free controls (Fig. 1B) . In contrast, the vast majority of CD20 þ TIL
showed an activated phenotype (IgD
, indicating they had undergone Ig class switching in response to antigen exposure (Fig. 1B) .
To further investigate whether CD20 þ TIL were antigen experienced, we sequenced up to 96 IgG heavy chain variable regions (including V, D, and J gene segments) from Fig. S1 ). Moreover, tumorinfiltrating B cells exhibited a high level of somatic hypermutation: on average 20 nucleotides were mutated in each approximately 400 nucleotide variable region, resulting in an average of 13 amino acid (aa) substitutions ( Fig. 2A) . This is consistent with reference values for antigen-experienced B cells ($18 nucleotide and 10 aa substitutions) versus naive B cells ($3 nucleotide and 3 aa substitutions; ref. 18) . Moreover, in all 3 tumors, there was evidence of B cells actively undergoing somatic hypermutation, as numerous sequences were identified with identical V-D-J junctions but distinct mutation patterns. An example of a clone with multiple mutated sequences is depicted in Fig. 2B .
Finally, the clonality of CD20 þ TIL was estimated by calculating the prevalence of each variable gene sequence in the dataset. Sequences were defined as clonal if at least 2 independent sequences contained identical V-D-J junctions but differing mutational patterns. Using these criteria, we found evidence for at least 11 to 14 B cell clones in each tumor, some of which were highly represented. For example, in IROC015, 16% of sequences were derived from a single B cell clone, an additional 17% of sequences were derived from 2 other predominant clones, a further 33% of sequences were derived from 8 minor clones, and the remaining 34% of sequences were unrelated (Fig. 2C ). These trends were very similar across all 3 patients (Fig.  2C ), indicating that CD20 þ TIL represent oligoclonal populations. Note that these are conservative estimates of clonal abundance, as we disregarded any identical sequences (i.e., sequences that had the same mutational profiles), reasoning that these could result from RT-PCR amplification of mRNA molecules derived from the same B cell. When the analysis was repeated with the inclusion of duplicate sequences, the predominant B-cell clones in each patient represented 22% to 24% of all sequences (compared with 8%-16% of sequences in the initial analysis). We saw no evidence of shared clonotypes between patients (Supplementary Fig. S1) (19, 20) . Of the target antigens identified to date, NY-ESO-1 and p53 are among the most frequently recognized in ovarian cancer (19, 20) , so these 2 antigens were selected for further analysis. By ELISA, 8 of 40 (20%) HGSC patients in cohort A showed a serum autoantibody response to NY-ESO-1 or p53 ( Fig. 4A and B) . Notably, these responses were equally prevalent in patients with or without CD20 þ TIL (19% vs. 20%, respectively; P ¼ 1.00; Fig. 4A and B) . Similar results were seen in an independent cohort of HGSC patients (n ¼ 30; cohort B), in which autoantibody responses were equally prevalent in patients with or without CD20 þ TIL (30% vs. 29%, respectively; P ¼ 1.00; data not shown).
To further address this issue, we assessed whether removal of CD20 þ TIL, which occurs during primary surgery and chemotherapy, abrogated tumor-specific serum autoantibody responses. We quantified autoantibody titers to NY-ESO-1 in 6 HGSC patients using serum samples collected before and 2 to 6 months after primary surgery. We selected serum samples that were collected as near as possible to the time of lowest tumor burden according to CA125 levels (Supplementary Table S3 ). Five of 6 patients showed an objective response to surgery and chemotherapy, as manifested by CA125 levels, CT scan, or physical examination. In most patients, autoantibody levels decreased after treatment, although one patient (IROC065) showed a reproducible increase (Fig. 4C) . Irrespective of these changes, all patients maintained high-titer NY-ESO-1-specific autoantibody responses (range: 1:3,200 to 1:204,800; Supplementary Table S3) (42) . We therefore assessed whether CD20 þ TIL might serve as APC to T cells, as described in other settings (23, 26, 42, 43) . Unfortunately, the low absolute numbers of CD20 þ TIL in human specimens precluded in vitro functional analyses. However, sufficient material was available to carry out multiparameter flow cytometry to determine whether CD20 þ TIL express cell-surface molecules involved in antigen presentation. CD20 þ TIL expressed MHC class I (pan-HLA-A, B, and C) and class II (HLA-DR) molecules, as well as CD40 (Fig. 5A) . Furthermore, CD20 þ TIL expressed the costimulatory molecules B7-1 (CD80) and B7-2 (CD86), albeit at moderate levels (Fig. 5A) . Accordingly, the majority of tumor-infiltrating CD4 þ and CD8 þ T cells displayed an activated effector phenotype (HLA-DR Fig. 5B ). Collectively, our results are consistent with the possibility that CD20 þ TIL serve as APC to T cells in the tumor environment.
CD8
þ and CD20 þ TIL colocalize in HGSC If B cells serve as APC in the tumor environment, they would be expected to be located in close proximity to T cells. To assess this, we carried out 2-color IHC with antibodies to CD8 and CD20. As previously reported, CD8
þ and CD20 þ TIL were found in both tumor stroma and epithelium ( Fig.  6A and B) . Intriguingly, CD8 þ and CD20 þ lymphocytes were frequently seen in close proximity, often in loosely structured aggregates (Fig. 6A) . Such aggregates were even found in tumors with low densities of TIL, suggesting the colocalization of CD20 þ and CD8 þ TIL was an active process. There were numerous examples in which CD8 þ and CD20 þ TIL were directly juxtaposed, consistent with cell-cell interactions ( Fig. 6C and D) . In summary, these imaging studies indicated that CD8 þ and CD20 þ TIL are frequently colocalized in HGSC, further supporting a possible role for CD20 þ TIL as APC.
The combination of CD8 þ and CD20 þ TIL is associated with prolonged survival in HGSC Finally, we used data from a large previously published cohort (6) to assess the relationship between CD20 þ and CD8 þ TIL and patient survival. CD20 þ and CD8 þ TIL were found in 41% and 84% of cases, respectively. Of the cases that were positive for CD20 þ TIL, almost all were also positive for CD8 þ TIL. Conversely, of the cases that were positive for CD8 þ TIL, approximately half also contained CD20 þ TIL. By Kaplan-Meier analysis, cases that were positive for both CD8 þ and CD20 þ TIL showed markedly greater disease-specific survival compared with those positive for CD8 þ TIL alone (Fig. 6E) . Thus, it seems that CD20 þ TIL can potently enhance the antitumor effect of CD8 þ TIL in ovarian cancer.
Discussion
We have investigated potential mechanisms by which CD20 þ TIL contribute to tumor immunity in HGSC, showed clear evidence of antigen exposure, including expression of activation markers, class switching to IgG, somatic hypermutation, and oligoclonality. The majority failed to express CD27, suggesting that they belong to a recently described subset of CD27 À memory B cells (39) (40) (41) 44) . Despite expressing IgG, CD20 þ TIL showed no correlation with tumor-specific serum autoantibodies and hence seemed to be uncoupled from humoral immunity. Instead, CD20 þ TIL correlated strongly with CD8 þ TIL. The 2 lymphocyte subsets were found in close proximity in tumor tissue, often in loose aggregates. CD20 þ TIL expressed surface markers characteristic of APC, including MHC class I, MHC class II, CD80, and CD86. Furthermore, tumors positive for both CD8 þ and CD20 þ TIL were associated with prolonged survival compared with those positive for CD8 þ TIL alone. Collectively, our results support the novel concept that CD20 þ TIL enhance tumor immunity through functional interactions with CD8 þ TIL.
Sequencing of IgG molecules from CD20 þ TIL yielded clear evidence of oligoclonality and somatic hypermutation, which are hallmarks of antigen exposure. The degree of B-cell clonality we measured in HGSC is similar to prior studies in breast cancer and germ cell tumors. Specifically, we found evidence for 11 to 14 B-cell clones in HGSC, compared with 6 to 13 clones in germ cell tumors (18) and 3 to 6 clones in breast cancer (12, 17) . Similarly, 58% to 66% of sequences were clonally derived in HGSC, compared with 18% to 79% in germ cell tumors and 30% to 69% in breast cancer. Notably, these are minimal estimates, as it is Nielsen et al.
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What antigens might be recognized by CD20 þ TIL?
Although this issue has yet to be addressed in HGSC, prior studies in breast cancer identified 2 antigens recognized by recombinant antibodies derived from tumor-infiltrating B cells: ganglioside D3 and a cleaved form of b-actin that was shown to become exposed on the surface of apoptotic cells (13, 45) . These results suggest that CD20 þ TIL responses reflect a breakdown of tolerance to self-proteins, possibly due to apoptosis of tumor cells. Identification of additional antigens recognized by CD20 þ TIL may yield further insights into the mechanisms by which B-cell responses are triggered and contribute to tumor immunity. Even though CD20 þ TIL express surface immunoglobulin, we found that they are not associated with serum autoantibodies to the common tumor antigens p53 and NY-ESO-1. This lack of correlation was seen across 2 independent cohorts of patients, as well as within individual patients undergoing cytoreductive surgery and chemotherapy. Although only 2 antigens were assessed, these are the most frequently recognized tumor antigens in HGSC identified to date (19, 20) . This finding is consistent with the fact that CD20 þ TIL are associated with prolonged survival in HGSC, whereas serum autoantibodies show little or no positive prognostic signal in most studies (31, (46) (47) (48) . Using two-color IHC, we showed that CD20 þ TIL are often found in close proximity to CD8 þ TIL (Fig. 6A-D) .
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Introduction
Many studies across a wide variety of human cancers have shown a clear association between the presence of tumorinfiltrating lymphocytes (TIL) and patient survival (1) (2) (3) (4) . To further understand this phenomenon, additional immune markers have been used to subdivide CD3þ T cells into functional subsets, with special emphasis on cytotoxic (e.g., CD8þ, nucleolysin TIA-1 isoform p40þ) and regulatory [e.g., CD4þ, interleukin 2 receptor subunit alpha (CD25)þ, FoxP3þ] phenotypes (3, 5) . Whereas TIL-expressing cytotoxic markers are generally associated with favorable prognosis, TIL-expressing regulatory markers (referred to as Tregs) were initially reported to correlate with poor prognosis (5) . This finding fit with the general notion that Tregs suppress adaptive immune responses and led many groups to pursue strategies to deplete Tregs from patients with cancer as a means to enhance tumor immunity (6) (7) (8) .
In the past decade, much effort has been devoted to finding molecular markers that uniquely define Tregs. Initially, these cells were characterized as CD4þ and CD25 high (9) . Further investigation revealed that Tregs express and functionally depend on the transcription factor forkhead box protein P3 (FoxP3; ref. 10). Indeed, humans and mice that lack an intact FOXP3 gene suffer a severe autoimmune syndrome known as immune dysregulation/polyendocrinopathy/enteropathy/X-linked syndrome in humans or the Scurfy phenotype in mice (10, 11) . Given its essential role in Treg development and function, FoxP3 became a popular single marker for Treg studies in cancer. Intriguingly, studies of the prognostic value of FoxP3þ T cells have lead to highly discrepant findings. In some studies, tumor-infiltrating FoxP3þ T cells have been associated with poor prognosis, consistent with the initial hypothesis that FoxP3þ Tregs inhibit antitumor immunity. In contrast, other studies have found that FoxP3þ T cells are associated with a favorable prognosis.
How can these widely discrepant prognostic claims be explained? On the one hand, they could reflect technical differences among studies, including the specific FoxP3 antibody used, scoring strategy, and statistical methods. Alternatively, the differing claims could reflect biologic factors. For example, it is conceivable that FoxP3þ T cells exhibit conventional regulatory (i.e., inhibitory) properties in some contexts but not others. Alternatively, FoxP3þ T cells may be consistently regulatory in nature but appear as favorable prognostic markers in some cancers because of their association with tumor-infiltrating CD8þ T cells or other effectors (12, 13) . Others have suggested that, in colorectal and gastric cancers, FoxP3þ T cells may inhibit tumor-promoting inflammatory responses to microbes, which could explain their association with favorable outcomes in these and similar contexts (14) . Finally, emerging evidence indicates that FoxP3 expression encompasses a heterogeneous population of cells that contain both regulatory T cells, which produce cytokines such as TGF-b1 and interleukin 10, and nonregulatory T cells, which may express interferon gamma and interleukin 17 (15-19; reviewed in ref. 20) . Given these various possibilities, it seems reasonable to question whether depletion of Tregs based on FoxP3 expression is likely to be beneficial or detrimental to patients with cancer.
To investigate this controversy, we did a comprehensive and critical review of the literature on tumor-infiltrating FoxP3þ T cells and prognosis in human cancer. Articles for review were identified during a PubMed search using the terms "FoxP3" and "cancer" and were vetted by title and abstract by one of the authors (R.J. deLeeuw). Several selection criteria were applied. First, we excluded studies of lymphoid cancers, because the immunologic nature of these malignancies makes it difficult to assess whether FoxP3þ T cells are acting directly on tumor cells or indirectly on antitumor effector lymphocytes. Second, we excluded studies that only correlated FoxP3þ T cells with late-stage disease as opposed to patient survival. Third, we included only those studies that measured FoxP3 expression by immunohistochemistry (IHC) or immunofluorescence to ensure that the intratumoral location of FoxP3þ cells was known. Finally, we reviewed a given data set only once, excluding secondary or tertiary studies that referred to a previously published data set.
In the end, we reviewed 58 studies encompassing 16 different cancer types (Table 1) , including bladder (19) , breast (21) (22) (23) (24) (25) (26) (27) (28) , cervical (29, 30) , colorectal (12, (31) (32) (33) (34) (35) (36) (37) (38) (39) , endometrial (40) (41) (42) , gastric (14, (43) (44) (45) (46) , head and neck (47) , hepatocellular (48) (49) (50) (51) (52) , lung (53, 54) , melanoma (55) (56) (57) (58) , mesothelial (59), oral (4, (60) (61) (62) (63) , ovarian (2, 3, 13, (64) (65) (66) (67) , pancreatic (68) , renal (69, 70) , and vulvar cancers (Supplementary Table S1 ; ref. 71) . The reported prognostic value of FoxP3þ T cells in these 58 studies ranged from poor (n ¼ 23), to neutral (n ¼ 23), to good (n ¼ 12). To better understand why the prognostic value of FoxP3þ T cells varies so widely, we assessed each study for technical factors (including the specific FoxP3 antibody used, scoring strategy, and the use of multivariate modeling) and biologic factors (including the use of additional markers to define Tregs and the tumor site studied).
Antibody Specificity
Different FoxP3 antibodies can yield different staining patterns, indicating that some antibodies may have suboptimal sensitivity or specificity (72, 73) . Although 18 of the 58 reviewed studies failed to state which specific FoxP3 antibody was used, within the remaining 40 studies, 11 different FoxP3 antibodies were used ( Table 1 ). The most commonly used antibody was a monoclonal designated 236A/E7. In the 23 studies that used 236A/E7, the prognostic significance of FoxP3þ T cells ranged from poor (n ¼ 10), to neutral (n ¼ 8), to good (n ¼ 5). Given that a single FoxP3 antibody can yield prognostic results this disparate, it seems that FoxP3 prognostic variability is not solely attributable to antibody selection.
Cell-Scoring Strategy
We investigated 4 aspects of the scoring strategies used to categorize tumors as positive or negative for FoxP3þ T cells: cutoff points, intratumoral location, use of tissue microarrays compared with whole sections, and computerized compared with manual counting (Table 1) . Although there is no standard cutoff point for TIL studies, 32 out of 58 of the reviewed studies used the median number of FoxP3þ T cells as the cutoff point. Within these 32, the distribution among poor, neutral, and good prognostic claims was 16, 11, and 5 studies, respectively. The remaining studies used a variety of scoring strategies, including the presence compared with absence of FoxP3þ T cells, the mean number of FoxP3þ T cells, or other criteria. A fairly even distribution among poor, neutral, and good prognostic claims was observed regardless of the cutoff point used (Table 1) . Thus, differing scoring strategies do not account for the variable claims of FoxP3 prognostic significance.
TIL can reside in tumor epithelium, stroma, or both, and this may influence their prognostic significance. Among the 58 reviewed studies, 15 did not discriminate between the
Translational Relevance
Although forkhead box protein P3þ (FoxP3þ) T cells are conventionally thought to suppress tumor immunity, this idea has been challenged by recent studies showing that, in some patient cohorts, tumor-infiltrating FoxP3þ T cells are associated with favorable prognosis. To investigate this apparent discrepancy, we did a comprehensive review of the literature on the prognostic significance of tumor-infiltrating FoxP3þ T cells in human cancer. We conclude that FoxP3 is inadequate as a single functional or prognostic marker. Moreover, the prognostic significance of FoxP3þ T cells can vary according to tumor site. Thus, the original view that FoxP3þ T cells invariably suppress tumor immunity is oversimplified. We require better understanding of the functional subtypes of FoxP3þ T cells and their biologic properties in different tumor microenvironments if we wish to rationally modulate their behavior to enhance tumor immunity. Table 1) . Regardless of the location of enumerated FoxP3þ T cells, a fairly even distribution was seen among poor, neutral, and good prognostic claims.
We next examined the use of tumor tissue microarrays (TMA) compared with whole sections (Table 1) . TMAs were used in 18 of the 58 studies, and prognostic claims ranged from poor (n ¼ 7), to neutral (n ¼ 6), to good (n ¼ 5). A similar range of prognostic claims was seen with studies using whole tissue sections. Regarding cell counting, 38 studies used manual counting by one or more investigators, 6 studies used a computer-based quantification method, and 14 studies did not state the counting method ( Table 1 ). Studies that used manual counting showed an unbiased spread among poor (n ¼ 16), neutral (n ¼ 14), and good (n ¼ 8) prognostic claims, regardless of the number of investigators who carried out cell counting. Definitive conclusions could not be drawn regarding the use of computerized counting, as only 6 studies used such methods, 3 of which involved colorectal cancer (see below).
Multivariate Correction for Stage or Grade of Disease
In principle, the density of FoxP3þ T cells could reflect the stage and/or grade of disease, which could influence prognosis. Of the 45 studies that correlated FoxP3þ T cells to stage and/or grade, 25 found a significant association between FoxP3þ T cells and the stage and/or grade of disease, with 11 reporting a P-value 0.001 (Supplementary Table S1 ). A potential confounding effect is that the quantity of TIL can influence nodal staging, especially in colorectal cancer (74) . Nonetheless, these studies support the possibility that FoxP3þ T cells could simply serve as a marker of more advanced disease. (Table 1) . Among these studies, the prognostic significance of FoxP3þ T cells ranged from poor (n ¼ 20), to neutral (n ¼ 11), to good (n ¼ 11). Notably, in 4 studies, FoxP3þ T cells were a significant univariate prognostic indicator, only to be removed during multivariate analysis. Of the 16 studies that did not use multivariate analysis, the potentially confounding effects of stage and grade were mitigated in most by the fact that (i) FoxP3þ T cells showed no prognostic significance even in univariate analysis or (ii) only specific stages or grades of disease were included in the study. In summary, even though FoxP3þ T cells are frequently associated with the stage and/or grade of disease, we found that this factor was well controlled in most studies and does not account for the variability of FoxP3 prognostication.
Multivariate Correction for Other TumorInfiltrating Lymphocyte Subsets
FoxP3þ T cells are usually found together with other TIL subsets, which can make it difficult to discern their independent prognostic effect. Although multivariate analysis can solve this problem, it requires that all TIL subtypes significant in univariate analysis be included in the multivariate model. In the 8 studies that included all TIL subsets in multivariate analysis, the prognostic value of FoxP3þ T cells ranged from poor (n ¼ 2), to neutral (n ¼ 3), to good (n ¼ 3; Table 1 ). Thus, although the number of studies is low, it seems that the prognostic significance of FoxP3þ T cells is not solely attributable to the presence of other TIL subpopulations.
Several studies made prognostic claims on the basis of the ratio of FoxP3þ T cells to other lymphocyte subsets, including CD3þ/FoxP3þ (n ¼ 2), CD4þ/CD25þFoxP3þ (n ¼ 1), CD68þ/FoxP3þ (n ¼ 2), CD8þ/FoxP3þ or FoxP3þ/CD8þ (n ¼ 18), CD8þ/CCR4þFoxP3þ (n ¼ 1), FoxP3þ/CD4þ (n ¼ 2), FoxP3þ/CD3þ/CD45ROþ (n ¼ 1), and Granzyme-Bþ/FoxP3þ (n ¼ 1; Supplementary Table S1 ). Among these 28 studies, prognostic claims for FoxP3þ TIL ranged from poor (n ¼ 12), to neutral (n ¼ 11), to good (n ¼ 5). Thus, the use of lymphocyte ratios has been inconsistently applied and yielded inconsistent prognostic claims.
Clinical Significance and Publication Bias
We next evaluated whether the magnitude of the prognostic effect was similar for studies claiming good compared with poor prognosis. Of the 58 studies, 32 reported multivariate hazard ratios for overall survival. A funnel plot revealed no significant difference between the magnitude of hazard ratios for studies claiming poor compared with good prognosis (Fig. 1) . Furthermore, there was no evidence of publication bias, as the studies were evenly distributed throughout the plot.
Use of Multiple Markers to Define FoxP3þ T Cells
Although FoxP3 was originally thought to uniquely define conventional CD4þ Tregs (75) , more recent studies indicate that, in some circumstances, FoxP3 can also be expressed by effector T cells (16, 18) . We assessed whether studies that subdivided FoxP3þ T cells using a second marker yield more consistent prognostic results. Of the 58 reviewed studies, 50 used FoxP3 as a sole marker, which resulted in variable prognostic claims ranging from poor (n ¼ 19), to neutral (n ¼ 19), to good (n ¼ 12; Table 1 ). The remaining 8 studies measured at least one marker in addition to FoxP3, including CD4, CD8, CD25, and C-C chemokine receptor 4 (CCR4). Four of these 8 studies showed that FoxP3þ T cells that coexpressed a second marker were associated with poor prognosis. The remaining 4 claimed that the identified subset did not have any prognostic significance. Of note, none of the 8 studies claimed an association with good prognosis.
On the basis of the above findings, we investigated more closely which markers were used in addition to FoxP3. Shah and colleagues used 2-color IHC to identify both CD4þFoxP3þ and CD8þFoxP3þ T cells in cervical cancer. Intriguingly, they found CD8þFoxP3þ T cells at a mean number of 3.32 per high-power field and CD4þFoxP3þ T cells at a mean number of 11.45 per high-power field (30) . Thus, had they used FoxP3 as a single marker, only $75% of the cells they measured would have been CD4þ T cells, which underscores the fact that not all FoxP3þ T cells are conventional Tregs. In another study, Watanabe and colleagues used coexpression of CCR4 to delineate a subset of FoxP3-expressing T cells in oral cancer (62) . An average of 58% of FoxP3þ cells were found to coexpress CCR4. Whereas total FoxP3þ T cells had no prognostic value (similar to 3 other studies of oral cancer; refs. 60, 61, 63), CCR4þFoxP3þ T cells showed a highly significant association with survival. These studies highlight the importance of using additional markers to account for the heterogeneity of FoxP3þ T cells.
Tumor Site and Subtype
It is conceivable that the biologic and prognostic effect of FoxP3þ T cells depends on microenvironmental context, in which case, tumor site and histologic and/or molecular subtype may be important factors. Indeed, when tumor site was taken into consideration, we found clear prognostic associations in some cases. For example, the 5 studies of hepatocellular cancer unanimously concluded that FoxP3þ T cells are associated with a poor prognosis (Table 1) . Conversely, 4 out of 10 studies investigating colorectal cancer concluded that FoxP3þ T cells correlated with a good prognosis, whereas the remaining 6 studies found no prognostic association. In considering colorectal cancer, Ladoire and colleagues recently hypothesized that the favorable prognostic effect of FoxP3þ T cells may reflect their ability to suppress tumor-promoting inflammatory responses to gut microbes (76) . In contrast to the above examples, the prognostic significance of FoxP3þ T cells remains controversial in several other cancers. In breast cancer, the reported prognostic effect of FoxP3þ T cells ranges from poor (n ¼ 5), to neutral (n ¼ 1), to good (n ¼ 2). Although ovarian cancer was one of the first tumor sites in which CD4þ Tregs were associated with poor prognosis (5), subsequent studies using FoxP3 as a marker are split among poor (n ¼ 1), neutral (n ¼ 4), and good (n ¼ 2) prognostic claims. Similarly, studies looking at gastric cancers show a split among poor (n ¼ 2), neutral (n ¼ 1), and good (n ¼ 2) prognostic claims. For the remaining 10 tumor sites, the number of published studies is insufficient to make definitive conclusions about the prognostic significance of FoxP3þ T cells.
In addition to tissue of origin, tumors can be classified based on their molecular features, as discussed recently by Ogino and colleagues (77) . Hence, it is conceivable that the variability of FoxP3þ T cell prognostication could be attributable to the inherent molecular heterogeneity within tumor types. In support of this idea, the prognostic value of FoxP3þ T cells is stronger in mismatch repair-proficient colorectal cancer compared with mismatch repair-deficient colorectal cancer (31) . Similarly, FoxP3þ T cells are prognostically significant in estrogen receptor (ER)þ but not ERÀ breast cancer (22, 27) . In uveal melanoma, FoxP3þ T cells provide prognostic significance in cyclooxygenase-2þ cases (58) . Although few in number, these studies suggest that the molecular subtype of tumors may influence the prognostic value of FoxP3 T cells.
Conclusions
Having critically reviewed the literature on the prognostic value of FoxP3þ T cells, we can make several recommendations for future studies. (i) We recommend that prognostic marker studies follow a standard reporting structure, such as the REMARK criteria (78) . (ii) In many cancers, FoxP3þ T cells are highly correlated with the stage and grade of disease; therefore, it is important to correct for these and other appropriate clinicopathologic factors. (iii) FoxP3þ T cells are invariably found with other lymphocytes; therefore, all TIL subsets with prognostic value should be included in multivariate models. (iv) The use of multiple markers to identify functional subsets of FoxP3þ T cells can lead to greater clarity about their prognostic value. (v) The prognostic value of FoxP3þ T cells seems to depend significantly on tumor site and possibly molecular subtype, suggesting that the biologic properties of FoxP3þ T cells are influenced by the tumor microenvironment in which they reside. Overall, this study provides a cautionary note for the concept of depleting FoxP3þ cells from patients with cancer as a means to enhance tumor immunity. Our findings suggest that this strategy may be beneficial for some tumor sites (e.g., liver) but detrimental to others (e.g., colorectal). Improved understanding of the different FoxP3þ T cell subsets in human cancer will likely enable the development of more precise and effective immunotherapies.
